Related Experiment Video
Updated: Mar 16, 2026

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy
Published on: July 19, 2024
Diagnosis and treatment of pulmonary alveolar microlithiasis
Nagehan Emiralioglu1, Burcin Beken1, Hatice Nursun Ozcan2
1Department of Pediatric Pulmonology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Abstract:
Pulmonary alveolar microlithiasis (PAM) is a rare genetic disease caused by mutations in sodium-phosphate co-transporter (SLC34A2), which encodes a type 2b sodium phosphate co-transporter. Disease is characterized by intra-alveolar microlith formation of phosphate. Turkey has a high prevalence of PAM. Herein, we report the clinical and radiological findings of three patients diagnosed with PAM and treated with disodium etidronate.
Insights
Pulmonary alveolar microlithiasis (PAM), a rare genetic lung disease, involves intra-alveolar phosphate microlith formation. This study reports on three Turkish patients treated with disodium etidronate.
Area of Science:
- Pulmonary Medicine
- Genetics
- Rare Diseases
Background:
- Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive genetic disorder.
- It is characterized by the accumulation of calcium phosphate microliths within the lung alveoli.
- Mutations in the sodium-phosphate co-transporter gene (SLC34A2) are the known cause of PAM.
Observation:
- Turkey exhibits a notably high prevalence of PAM.
- This report details three cases of PAM diagnosed in Turkish patients.
- Clinical and radiological findings were documented for each patient.
Findings:
- All three patients were treated with disodium etidronate.
- The study focuses on the clinical and radiological outcomes following this treatment.
- Specific treatment efficacy data is presented.
Implications:
- Disodium etidronate may represent a potential therapeutic option for Pulmonary alveolar microlithiasis.
- Further research into bisphosphonates for PAM treatment is warranted.
- Understanding the high prevalence in Turkey could inform targeted screening and genetic counseling efforts.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Mitral Stenosis III: Medical Management

